AbbVie scientists are working to combine deep biologic knowledge with cutting-edge research technology to accelerate the delivery of advancements in cancer.
We’re curious and we’re basically problem solvers. So, day-to-day, we’re in there trying to solve the next problem.
Saul Rosenberg, Ph.D., senior director of oncology research, AbbVie
Regulated cell death – apoptosis
Apoptosis is a form of regulated cell death, a natural process that eliminates damaged, unneeded or dangerous cells from the body.1 Through our deep knowledge of apoptosis and the role impaired apoptosis can play in the proliferation of cancer cells, we are advancing novel cancer research.
Immuno-oncology therapies aim to use the body’s own immune system to help fight cancer.2 Regular function of natural immune effector mechanisms for tumor detection and elimination may help prevent the growth and spread of tumors.
Interfering with the communication signals of malignant B cells is a potential strategy for treating some types of cancer.3 AbbVie is investigating key enzymes in the B cell receptor signaling complex that play an important role in the survival and expansion of malignant B cells.
Novel tumor targeting
Antigens are markers on cells that can be used to specifically target
cells that express the marker, including cancer cells, with
therapeutic agents.4 The ideal antigen is present on cancer
cells but not on normal cells. At AbbVie, we are leveraging our
expertise across multiple technology platforms to identify novel
antigens and research therapeutic approaches needed to target
You have to have people that are willing to go the extra mile—and we do. At the end of the day, all of us are here to see these molecules in cancer patients.
Steve Davidsen, Ph.D., vice president of oncology discovery, AbbVie
The potential of protein degradation
By hijacking cells’ protein disposal system, AbbVie scientists are
unlocking new possibilities for challenging diseases.
 Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell
survival and oncogenesis. Oncogene. 2003;22:8590-8607.
 Cancercare.org. Understanding the Role of Immuno-Oncology in Treating Cancer- Immuno-Oncology. Retrieved from: https://www.cancercare.org/publications/285-understanding_the_role_of_immuno-oncology_in_treating_cancer. Accessed January 2019.
 Burger, JA, Ghia P, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009. 114:3367-3375
 Alatrash G, Crain, A, et al. Chapter 7 – Tumor-Associated Antigens. Immune Biologic Allogeneic Hematopoeitic Stem cell Transplantation. 2019(2):107-125.
National Cancer Institute (2018). NCI Dictionary of Cancer Terms: Antibody. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody.
 Jarvis, LM. Targeted Protein Degraders Are Redefining How Small Molecules Look and Act. Chemical & Engineering News. https://cen.acs.org/articles/96/i8/targeted-protein-degraders-are-redefining-how-small-molecules-look-and-act.html. Accessed March 2019.
 Peters, C. & Brown, S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015. 35:1-20.
 Dana Farber Cancer Institute. (2019). CAR T-Cell Therapy. [online] Available at: https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/. Accessed November 2020.